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Summary The inhibitory effect of c-myb antisense oligodeoxynucleotides (ODNs) conjugated to folic acid
(FA) on HL-60 cell proliferation was examined. Folic acid was covalently linked to a polylysine chain and
purified by gel chromatography. Sterile FA-polylysine was complexed with c-myb sense and antisense.
Exposure of HL-60 cells to the FA-polylysine-c-myb antisense ODN complex resulted in a down-regulation
of c-myb expression and a greater inhibition of proliferation than that obtained using free ODNs. Moreover,
FA-polylysine conjugate alone or complexed to c-myb sense ODN was not toxic to cells. The antigenic
properties and uptake of the vitamin were not affected by the polylysine chain. These data suggest that this
strategy is potentially useful for the selective delivery of anti-oncogene-targeted ODNs into cancer cells.
Antisense oligodeoxynucleotides (ODNs) have proven useful
for selective inhibition of gene expression (Holt et al., 1988;
Szczylik et al, 1991). However, their rate of cellular uptake
appears to be quite slow, and consequently attempts have
been made to enhance their stability and their delivery into
cells. For instance, receptor-mediated endocytosis has been
used to increase the uptake of synthetic ODNs and other
foreign molecules such as proteins complexed to specific
ligands (Wu & Wu, 1987, 1988; Cotten et al., 1990; Leamon
& Low, 1991; Citro et al., 1992; Manfredini et al., 1993).
Since the receptors for some growth factors, vitamins and
hormones are overexpressed in rapidly dividing tumour cells
(Rothemberg & Da Costa, 1971; Asok et al., 1981; Sclhub &
Franklin, 1984; Lacey et al., 1989), the ligands of these
receptors can be exploited to selectively introduce therapeutic
compounds into the cells. The use of modified ligands for
specific cell-surface receptors as carriers of oncogene-targeted
antisense ODNs represents a potentially useful therapy to be
used alone or in combination with antineoplastic drugs.
We have previously reported that a c-myb antisense-
transferrin-polylysine complex produces an enhanced uptake
into HL-60 cells, resulting in an increased biological effect.
Recently, we have also observed that a polylysine chain
covalently linked to compounds such as insulin, folic acid,
retinoic acid, oestrone and testosterone can be used for
specific interactions with nucleic acids in physiological ionic
conditions (G. Citro, unpublished observation).
The presented study describes the efficacy of folic acid
receptor-targeted c-myb antisense in the HL-60 cell line. The
effect ofthe complexed phosphodiester (PO) ODNs was com-
pared with that of phosphorothioate (PS) ODN antisense
given alone.
With doses of 20 and 30figmlVl, we found that PS c-myb
antisense actively inhibited the rate of the cell proliferation
while free PO c-myb antisense had no effect. However, when
free PO c-myb antisense ODNs were complexed to FA-
polylysine, their inhibitory effect on the cell proliferation was
even greater than that obtained using the free PS oligos.
Furthermore, whereas recent research has indicated there are
some drawbacks to the use of PS oligos in systemic therapy
(Stein & Cheng, 1993), PO oligos might prove useful since
their metabolites are similar to physiological compounds,
resulting in less aspecific toxicity.
Materials and methods
Folic acid-polylysine andoligodeoxynucleotide conjugates
Folic acid (FA) was dissolved in 20mM sodium phosphate
buffer at pH 4.5 and incubated with a 6-fold molar excess of
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a water-soluble I-ethyl-3(3-dimethylaminopropyl) carbodi-
imide hydrochloride (Pierce) for 1 h at room temperature. A
3 M excess of the modified vitamin was then added to the
polylysine solution (MW 21,000 in 20 mm sodium phosphate,
pH4.5) and incubated overnight at room temperature. The
same procedure was performed to obtain the FA-fluores-
ceinated polylysine complex (Sigma).
The conjugate was purified by Sephadex G-25 gel
chromatography (100mM phosphate saline buffer pH 7.4)
monitoring spectrophotometrically the eluate at 287 nm. The
extent of FA conjugation to polylysine was determined spect-
rophotometrically at 363 nm (folic acid F. = 6,200 in PBS,
pH 7.4). In addition, folate conjugate was identified by using
a minimum amount of [3Hjfolic acid (Amersham) in the
reaction mixture. In order to eliminate unbound or absorbed
FA, the purified complex was extensively dialysed in 100 mM
phosphate-buffered saline solution at pH 7.4 (1,000 mlday-'
for 4 days) at 4°C. To verify that the unbound or absorbed
FA was completely removed, gel filtration chromatography
(Sephadex G-25) in the presence of high ionic strength (2 M
sodium chloride in PBS, pH 7.4) was performed.
Phosphorothioate and phosphorodiester ODNs correspon-
ding to c-myb codons 2-7 (18-mer) were supplied by Applied
Biosystems (CA, USA). The sense and antisense c-myb
sequences were 5'-GCC CGA AGA CCC CGGCAC-3' and
5'-GTG CCG GGGTCT TCG GGC-3' respectively. Sterile
FA-polylysine (30 nggAl-') was mixed with c-myb antisense or
sense ODNs and left for 1 h at room temperature.
Immunoslot blot
Purified FA-polylysine samples (20pl) containing various
amounts of FA were immobilised on nitrocellulose filters
(Bio-Rad) using a Bio-Dot SF Microfiltration apparatus
(Bio-Rad) following the manufacturer's suggestions.
Slots were incubated first with anti-FA monoclonal
antibody (clone VP 52; mouse IgG2b; Sigma), then with goat
anti-mouse horseradish peroxidase (HRP) conjugate, and
developed using the HRP substrate 4-chloronaphthol. The
polylysine not complexed to folic acid was used as a control
to verify the absence of aspecific immunoreactivity.
Fluorescence microscopy
To ensure the same amount of fluorescein (FITC) in both
compounds used in cell treatments, FITC-polylysine (Sigma)
was coupled to FA or left unconjugated as control.
HL-60 cells (106ml-') were incubated for different lengths
of time (from 5 to 300min) at 37°C with FITC-polylysine-
folic acid conjugate (final concentration of folic acid 10-7M).
Cells were then washed five times with cold PBS, cytocent-
rifuged (Shandon) and fixed at 4°C in absolute acetone for
15 min. Cells were photographed through a Leitz microscope
with a 40 x phase-contrast/fluorescence objective.
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Formation ofthefolic acid-polylysine-c-myb
olygodeoxynucleotide complexes
Sterile FA-polylysine (30 ngpth') was mixed with various
amounts of c-myb antisense or sense ODN in sterile aqueous
solution. Complexes were allowed to form for 1 h at room
temperature before being added to the cells.
Cells and culture conditions
Human promyelocytic leukaemia cells (HL-60) were grown in
suspension in a humidified atmosphere of 95% (v/v) air and
5% (v/v) carbon dioxide at 37°C in RPMI-1640 and 10%
heat-inactivated fetal calf serum supplemented with
102 tLg ml1 penicillin G, 102gLgml-' streptomycin and
120 ltg ml-' L-glutamine. The cells were grown to densities of
1 x 105 cells before harvesting (Collins et al., 1977; Koeffier,
1983). For all the experiments, cells were cultured in 24 well
Costar plates at an initial concentration of 1 x 104 in RPMI-
1640 folate-deficient medium prepared according to Barton
and Capdevila (1986). Doses of 10 or 20 igml1' ODNs were
added to cells, followed by two subsequent doses of 5 tLg at
24 and 48 h. The control cells were treated with the same
doses of FA-polylysine conjugate (10-7 M) used in the oligo
complex preparation.
Cell number and viability were determined using an elect-
ronic particle counter and trypan blue exclusion assay every
2 days.
c-myb mRNA levels in HL-60 cells
Reverse transcription-polymerase chain reaction (RT-PCR)
for detection of c-myb mRNA transcripts was carried out as
previously described (Chomczynski & Sacchi, 1987; Ven-
turelli et al., 1990). A 3' ODN primer c-myb corresponding
to nucleotides 2,466-2,487 and a 5' ODN primer c-myb
corresponding to nucleotides 2,258-2,279 of the published
cDNA sequence were utilised (Majello et al., 1986). After 30
cycles, 10 l of amplified product was electrophoresed on a
4% agarose gel and then transferred to a nylon filter. Filters
were prehybridised and then probed with a 32P-end-labelled
oligonucleotide probe (Sambrook et al., 1989) corresponding
to a 50 base c-myb oligomer sequence contained within the
amplified region from nucleotides 2,351 to 2,400. As control,
P-actin mRNA was amplified with ,-actin-specific primers
and detected with a specific probe, as described by Nicolaides
et al. (1991). Hybridisation was detected by autoradiography.
Results
Purification ofthefolic acid-polylysine conjugate
The elution profile of the polylysine and FA mixed in the
absence of the coupling agent is shown in Figure 1 (top).
Two separated peaks were observed under physiological ionic
conditions (100 mM phosphate buffer saline, pH 7.4).
Fluoresceinated polylysine was recovered in fractions 4-8,
while free folic acid was collected from fractions 23-35. The
fluoresceinated polylysine-FA conjugate eluted in the exc-
luded volume shows (Figure 1, bottom) as a single sharp
peak with a strong UV absorption at 287 nm. The conjugate
rechromatographed at high ionic strength (2M sodium
chloride in PBS, pH 7.4) showed a similar elution profile,
demonstrating that the compounds were covalently bound

























Figure 1 Sephadex G-25 chromatography of the FA-polylysine
conjugate. Purification of FA-polylysine conjugate was per-
formed by gel chromatography on Sephadex G-25 in 10mM
sodium phosphate pH 7.4 (bottom). [3H]FA (25 x 105c.p.m.) was
added to the reaction mixture as radioactive tracer. FITC-
polylysine (MW 11,000; Sigma) was used as marker to identify
the fractions where the free polylysine was eluted (top).
tration of complexed FA (from 3 to 300 ng). The staining
confirms the results reported in Figure 1 concerning the
covalent link between FA and polylysine. Since free FA is
not able to bind to the nitrocellulose membrane, any weakly
linked FA would have been removed during the experiment
by the antibody (owing to the affinity of the immunological
reaction) or by the washes done in the test.
Uptake offolic acid-fluoresceinatedpolylysine
HL-60 cells treated with FA-FITC-polylysine conjugate









Immunodetection offolic acid in the conjugate
As the specific MAb used was able to recognise both FA and
its active metabolite, the conjugation of FA with polylysine
chain did not alter the active site of the FA molecules. The
specific MAb showed a dose-dependent reaction with the
vitamin in the conjugate. Figure 2 shows the results of a slot
blot assay (in duplicate) obtained using an increasing concen-
Figure 2 Immunoslot blot. Amounts of FA-polylysine conjugate
containing FA (from top to bottom: 300, 60, 30 and 3 ng) were
blotted in duplicate onto nitrocellulose filter. After incubation
with specific anti-folic acid MAb, the bound MAb molecules were
then reacted with a goat anti-mouse IgG horseradish peroxidase
conjugate. Enzymatic activity was detected via colour develop-
ment as described in Materials and methods. Free polylysine
1 mgml- was used as negative control.c-myb OLIGONUCLEOTIDES DELIVERY INTO LEUKAEMIA CELLS 465
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Figure 3 Uptake of FA FITC-polylysine conjugate. Phase-contrast a, b and fluorescence d, e micrographs of HL-60 cells
incubated with FITC-polylysine conjugate. The micrographs shown refer to the incubation time of 15 and 120 min respectively.
Phase-contrast c and fluorescence f micrographs refer to HL-60 cells treated with FITC -polylysine lacking FA (incubation
time = 120 mi).
brane. The complex bound to the cell surface in 5-O min
(Figure 3d) and then gradually entered the cell cytoplasm
over a period of 2-5 h with the fluorescence distributed in a
somewhat patchy pattern (Figure 3d and e). In contrast, cells
treated with FITC-polylysine lacking FA showed no
fluorescence (Figure 3f). The presence of a 100-fold molar
excess of free folate in the medium resulted in a significant
decrease in the fluorescence intensity indicating that the
uptake of FA-polylysine complex (as with FA) is mediated
via the FA receptor mechanisms (data not shown).
Figure 4 Gel shift of oligodeoxynucleotide with FA-polylysine
complexes. a, Three nmoles of native FA incubated with 10 nmol
of c-myb antisense ODNs. b, Three nmoles of FA-polylysine
incubated with 10 nmol of c-myb antisense ODNs. c, c-myb
ODNs in distilled water. Samples were separated by electro-
phoresis on 1% agarose gel at 100 V with 1 x TAE (40mM
Tris-acetate/l mM EDTA, pH 8) running buffer.
Formation offolic acid-polylysinelc-myb oligodeoxynucleotide
complexes
Complexes of FA-polylysine with c-myb ODNs were
obtained as described in Materials and methods. Oligo bind-
ing to the FA-polylysine complex was demonstrated by gel
mobility-shift assay (Figure 4). It is evident that ODN mixed
with FA or alone migrated to the positive charged pole
(Figure 4a and c). On the other hand the negative charge of
the ODN when complexed to the FA-polylysine conjugate
was completely neutralised by the polylysine chains (Figure
4b).
Effect offolic acid-polylysine-oligodeoxynucleotide complex
on theproliferation ofHL-60 cells
HL-60 cell proliferation is inhibited by exposure to c-myb
antisense ODNs in excess of 10 jaM (Anfossi et al., 1989;
Ferrari et al., 1990; Nicolaides et al., 1991). In agreement
with our previous results (Citro et al., 1992), 20 and
30tsg ml1l doses of free phosphodiester (PO) c-myb antisense
ODNs had no effect on the HL-60 cell proliferation. Indeed,
after 6 days the cell number of all the treated cells was
similar to that of the control: PO sense 201sgml-' =540 +
7 x 102; PO sense 30ljg ml-' = 515 ± 15 x 102; PO antisense
20 igml-' = 490 ± 10 x 102; PO antisense 30igml-' =
495 ± 20 x 102; control = 520 ± 10 x 102. However, doses of
20 and 30 tgml1' phosphorothioate (PS) c-myb antisense
ODNs clearly impaired HL-60 cell proliferation (Figure 5a).
The same doses of ODNs phosphodiester complexed to the
FA-polylysine conjugate induced a dose-dependent inhibition
of HL-60 cell proliferation (Figure Sb) which was much
greater than the inhibition induced by free phosphorothioate
ODNs (Figure Sa). Moreover, the proliferation rate of HL-60
cells exposed to the FA-polylysine-sense ODN complex was
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Figure 5 Effect of FA-polylysine-c-myb antisense oligodeoxy-
nucleotides complexes on HL-60 cell proliferation. Cell numbers
and viability were determined every 48 h. Each point is an
average ± s.e. of three separate experiments with three replicate
samples for each point. Different preparations of oligo were
employed. a, Phosphorothioate c-myb oligomers: 0, control; A,
sense 20psgml1; 0, sense 30sgmlh'; *, antisense 20pgml-';
0, antisense 30pgml'; b, FA-polylysine-c-myb phosphodiester
complexes: 0, control; A, FA-sense 20 sgml-'; 0, FA-sense
30sgml-'; U, FA-antisense 20 sgml-'; 0, FA-antisense
30pgml-'.
inhibition of HL-60 cell proliferation with the FA-polylysine/
c-myb antisense ODN complex correlated with c-myb tran-
script levels, total mRNA was extracted from cells treated
with the FA-polylysine conjugate (Figure 6c) or the FA-
polylysine-c-myb sense ODN complex (Figure 6, lane s) or
the FA-polylysine-c-myb antisense ODN complex (Figure 6,
lane as), and c-myb expression was measured by RT-PCR.
c-myb mRNA was barely detectable in cells treated with the
FA-polylysine-c-myb antisense ODN complex, while it was
highly expressed in sense-treated and control cells (Figure 6).
Densitometric measurement of the c-myb hybridising band in
sense-vs-antisense oligodeoxynucleotide-treated samples indi-
cated that the signal from the antisense-treated samples was
<5% of that from the sense-treated samples.
Discussion
In this study we present a protocol for the synthesis and
purification of a covalent conjugate of FA and polylysine
Figure 6 The expression of c-myb mRNA in HL-60 cells
exposed to FA-polylysine-c-myb oligodeoxynucleotide complexes.
HL-60 cells (I0O ml-1) were incubated in the presence of the folic
acid-polylysine conjugate alone (c), or exposed for 24 h to
30 lAg ml- c-myb sense (s) or antisense (as) ODNs complexed to
the FA-polylysine conjugate. Cells were harvested and total
RNA isolated and divided into two equal portions that were
separately amplified by RT-PCR with c-myb- and P-actin-specific
primers as described. The resulting cDNAs were hybridised to
specific 32P-end-labelled probes. Results are from a representative
experiment. Identical qualitative results were obtained with 40 or
50 RT-PCR amplification cycles.
chain (Figure 1) to be employed as vehicle for ODNs.
As shown in Figure 2 the covalent coupling of a polylysine
chain to FA did not prevent the ligand being recognised by
specific monoclonal antibodies, suggesting that FA main-
tained its biological activity. Other authors also provide
evidence to support this hypothesis (Leamon & Low, 1991).
Indeed, they found that FA covalently linked to proteins of
different sizes was still recognised by specific monoclonal
antibodies as well as by FA cell-surface receptors. Moreover,
the immunoassay presented here can be used to recognise the
FA-polylysine complex in the medium as well as in biological
fluids in vivo. The addition of the polycation peptide to FA
resulted in a conjugate capable of binding to ODNs in
physiological conditions. Owing to the cationic properties of
the polypeptide chain, the FA-polylysine conjugate was able
to avidily bind negatively charged ODNs, as shown in the
band-shift experiments (Figure 3). The fluorescence micros-
copy results (Figure 4) clearly indicate that the conjugate
interacts with the cell membrane after a few minutes and
then enters the cells. Therefore, as this process can be com-
petitively blocked by free folate, it would appear that the
cells are capable of internalising folate conjugates through a
folate receptor-mediated mechanism (Barton & Capdevila,
1986). The non-lysosomal pathway internalisation of folate
into the cells (Rothemberg et al., 1990; Asok, 1992; Weitman
et al., 1992) allows the ODNs-FA-polylysine complex to
enter directly into the cytoplasmic compartment. Because of
Watson-Crick base pairing specificity, the ODNs can react
with the complementary c-myb mRNA inside the cells, thus
inhibiting cell proliferation. The high inhibitory effect on cell
proliferation displayed by complexed ODNs can be ascribed
to both their stability outside the cells and the increased
uptake obtained by the receptor-mediated event. The FA-
polylysine chain can form a complex with an ODN in the
medium, thereby shielding it from nuclease attack. These
observations are in agreement with data of other authors
(Farber et al., 1975; Stein & Cheng, 1993). As with the
delivery system based on the use of a transferrin-polylysine
complex (Citro et al., 1992; Manfredini et al., 1993), the
system described here represents a useful means of targeting
and of intracellular uptake of ODNs into tumour cells. Fur-
thermore, this study also shows that the FA-polylysine c-myb
antisense complex, unlike FA-polylysine c-myb sense,
specifically reduces the c-myb mRNA level in treated cells
(Figure 6).
Taking into account the receptor expression on the tumour
cell membranes, two or more vehicles carrying antisensec-myb OLIGONUCLEOTIDES DELIVERY INTO LEUKAEMIA CELLS 467
ODNs directed against the encoded mRNAs can be made.
The ideal surface receptors to exploit for a selective delivery
of antisense ODNs would undoubtedly be those exclusively
expressed by tumour cells. Alternatively, receptors which are
overexpressed in some neoplastic cells, such as the EGF, the
transferrin (Klausner et al., 1983; Simons et al., 1992) and
the FA receptors (Klausner et al., 1983; Kamen et al., 1988;
Hopkins et al., 1990; Asok, 1992; Simons et al., 1992; Weit-
man et al., 1992; Berczi et al., 1993), could also be used.
Recent results (Ratajczak et al., 1993; T. Skorski et al.,
1994) indicate that anti-oncogene-targeted phosphorothioate
ODNs administered in vivo possess antitumoral activity
against tumour cells, resulting in an increase in animal sur-
vival. Yet a relative paucity of phosphorothioate vs phos-
phodiester successes in tissue culture when targeted to mam-
malian mRNAs has also been reported (Stein & Cheng,
1993). Consequently, complexed phosphodiester ODNs
should perhaps be considered as their metabolites are less
toxic to the cells. However, as with any other drug in the
developmental process, further studies are required to assess
the potential role of antisense oligodeoxynucleotides in
therapeutic applications.
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